Clinical trials: Graft vs Host Disease
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
Acute Graft Versus Host Disease
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri®) with the standard treatment, the use of steroids, as a new treatment for acute graft versus host disease…
- Trial name
- NCT02133924
- Testing
- natalizumab, steroids
- Where
- 12 sites in United States
- Volunteers
- 76 people
- Sponsor
- John Levine
Hematologic Diseases, Acute Leukemia in Remission
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of…
- Conditions
- Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase
- Trial name
- NCT03842696
- Testing
- Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine)
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Chronic Pain, Chronic Pain Syndrome
Collaboratory Treatment Pathway for Chronic Pain Patients.
In this multicenter randomized controlled trial, the aim is to evaluate the effectiveness of a standardized treatment pathway (STP) for patients referred to four participating pain clinics, by comparing it to treatment as usual…
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic (Non-malignant) Musculoskeletal Pain, Patients Referred to Multidisciplinary Pain Clinics
- Trial name
- PainPath (NCT07331766)
- Testing
- A collaborative treatment pathway for patients referred to multidisciplinary pain clinics in Norway, Treatment as usual
- Where
- 4 sites in Norway
- Volunteers
- 386 people
- Sponsor
- St. Olavs Hospital
Acute Graft Versus Host Disease
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
This is a clinical trial to see if treatment with etanercept for early skin graft-versus-host disease (GVHD) can effectively treat and prevent progression of the disease without using high dose steroids.
- Trial name
- NCT00726375
- Testing
- Etanercept (Enbrel)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Heart Disease
Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors
A study to examine the effectiveness of a multilevel Community Health Workers intervention as an adjunct to routine primary care in reducing CVD risk factors among diabetic Latinos in Miami.
- Conditions
- Diabetes, Heart Disease, Hypertension
- Trial name
- MHHI (NCT01152957)
- Testing
- CARIÑO Project, Enhanced Usual Care
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Miami
Lung Transplantation, Allografts
Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
A controlled randomized, open-label, multi-centre study evaluating if an immunosuppressive protocol, based on ATG-induction, once daily tacrolimus-dose (Advagraf®), mycophenolate mofetil and corticosteroid reduces the incidence…
- Trial name
- ScanCLAD (NCT02936505)
- Testing
- Cyclosporine, Mycophenolate mofetil (MMF), Rabbit Anti thymocyte globulin
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 249 people
- Sponsor
- Vastra Gotaland Region
Hematologic Malignancy
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies
This research study is studying the removal of a subset of white blood cells (called alpha/beta T cells) from the donor product using a cell separation device before the product is transplanted into the participant.
- Trial name
- NCT03717480
- Testing
- ClinicMACs
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
GVHD,Acute, Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD
Acute graft versus host disease (aGvHD) is a severe and potentially fatal complication of allogeneic hematopoietic stem cell transplantation (HCT).
- Trial name
- NCT05368181
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sichuan University
GVHD
Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT
The risk of Graft-versus-host Disease(GVHD) is significantly associated with the mortality rate of patients undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT06334367
- Testing
- CD25 treatment, low-dose ATG
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Wang Xin
Central Serous Chorioretinopathy
Eplerenone for the Treatment of Central Serous Chorioretinopathy
To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
- Trial name
- NCT01990677
- Testing
- 25mg Eplerenone
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Wills Eye
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Grade B aGVHD, Grade C aGVHD
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to…
- Conditions
- Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
- Trial name
- NCT02336230
- Testing
- remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mesoblast, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell…
- Trial name
- NCT00678275
- Testing
- ATG FRESENIUS (Anti-Lymphocyte-Globulin)
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Respiratory Diseases, Chronic and Acute Respiratory Failure
Validation of a Simulated Clinical Evaluation of Ventilators
The purpose of this study is to evaluate the ability of a device reproducing patients' respiratory characteristics to select in-VITRO the most appropriate ventilator for a given pathology.
- Trial name
- SIMULVENTI (NCT01113255)
- Testing
- bench-evaluation, of three ventilators
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Malignancies
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
The purpose of this study is to determine if Velcade (also known as bortezomib) can help prevent graft versus host disease (GVHD) developing after transplantation.
- Trial name
- NCT00369226
- Testing
- Bortezomib (Velcade), Tacrolimus, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Cough
The Utility of feNO in the Differential Diagnosis of Chronic Cough
In this study the investigators wish to explore the difference in 24 hr. cough counts measured using the Hull Automated Cough Counter (HACC), from baseline and after two weeks treatment with either montelukast or prednisolone in…
- Trial name
- TUF (NCT02479074)
- Testing
- Montelukast (High FeNO group), Prednisolon, Montelukast (High FeNO), Montelukast (Low FeNO group)
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity and mortality. Steroids remains first line therapy for acute GVHD but there is currently no consensus on second line therapy for those in…
- Trial name
- NCT00563108
- Testing
- Basiliximab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hospital Authority, Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.